

Contents

PUBLICATIONS	iv
ACKNOWLEDGEMENTS	ix
LIST OF FIGURES	xi
LIST OF TABLES	xii
ABBREVIATIONS	xv
SUMMARY	xix
ZUSAMMENFASSUNG	xxi
1 INTRODUCTION	1
1.1 Peptides in Drug Discovery	1
1.1.1 Peptide Mimetics and their Advantages	3
1.2 Plasma Membrane	6
1.2.1 Membrane Model	6
1.2.2 Cholesterol	8
1.2.3 Membrane Asymmetry	9
1.2.4 Membranes in Cancer	10
1.3 Anticancer Peptides	12
1.3.1 Anticancer Peptides as New Cancer Therapy	12
1.3.2 Mechanism of Action	13
1.3.3 Structure-Activity Relationship	15
1.3.4 Self-Association	16
1.3.5 Selectivity	18
1.4 Targeted Drug Therapy for Cancer	20
1.4.1 Peptide-Based Targeted Drug Delivery	20
1.4.2 Conjugates Containing a Membranolytic Peptide	21
1.5 Computational Peptide Design	23
1.5.1 Molecular Representation of Peptides	23

1.5.2	Simulated Molecular Evolution	25
1.5.3	Recurrent Neural Networks	27
2	AIM OF THE THESIS	31
3	MATERIALS AND METHODS	33
3.1	Experimental Methods	33
3.1.1	Peptide Synthesis and Analytics	33
3.1.2	Cytotoxicity Assay	34
3.1.3	Liposome Preparation	35
3.1.4	Lipid Concentration Assay	37
3.1.5	Liposome Disruption Assay	37
3.1.6	Giant Vesicle Rupturing	38
3.1.7	Circular Dichroism	39
3.1.8	Temperature Profiling in Reversed-Phase Chromatography	40
3.1.9	Native Electrospray Ionization Mass Spectrometry (ESI-MS)	40
3.1.10	Antibody-ACP Conjugation	41
3.1.11	Acetazolamide-ACP Synthesis	42
3.2	Computational Methods	43
3.2.1	Software	43
3.2.2	Simulated Molecular Evolution Implementation	43
3.2.3	Recurrent Neural Network Implementation	44
4	RESULTS AND DISCUSSION	49
4.1	Simulated Molecular Evolution for Anticancer Peptide Design	49
4.1.1	Introduction and Motivation	49
4.1.2	Activity Optimization of ACPs	50
4.1.3	Analysis of ACP Properties	54
4.1.4	Self-Association of ACPs	59
4.1.5	Discussion	60
4.2	Designing Anticancer Peptides by Constructive Machine Learning	63
4.2.1	Introduction and Motivation	63
4.2.2	Model Application	63
4.2.3	Analysis of Physicochemical Properties	67
4.2.4	Discussion	68
4.3	Activity and Selectivity Comparison of Anticancer Peptides between Cells and Liposomes	69
4.3.1	Introduction and Motivation	69
4.3.2	Liposome Composition	70

4.3.3	General Model Description	72
4.3.4	Liposome Disruption Assay Model	75
4.3.5	Circular Dichroism Model	77
4.3.6	Model Validation with External Dataset	80
4.3.7	Giant Vesicle-Rupturing	83
4.3.8	Discussion	85
4.4	Anticancer Peptides as Cytotoxic Payloads in Targeted Drug Therapy	88
4.4.1	Introduction and Motivation	88
4.4.2	Antibody-ACP Conjugate	89
4.4.3	Acetazolamide-ACP Conjugates	90
4.4.4	Discussion	92
5	CONCLUSIONS AND OUTLOOK	95
	BIBLIOGRAPHY	101
A	SUPPLEMENTARY INFORMATION	123
A.1	Analytical Data Peptides and Peptide-Conjugates	123
A.2	Cytotoxicity Assay MCF-7 cells	153
A.3	Cytotoxicity Assay HDMEC	182
A.4	Hemolysis Assay	191
A.5	Liposome Disruption Assay	204
B	CURRICULUM VITAE	225